Literature DB >> 17640844

Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.

E Facchiano1, S Scaringi, R Kianmanesh, J M Sabate, B Castel, Y Flamant, B Coffin, S Msika.   

Abstract

AIMS: To review our experience of laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of malignant ascites from advanced gastric cancer in order to discuss benefits, problems and possible indications.
METHODS: From June 2000 to May 2003 laparoscopic approach was used to perform HIPEC on five patients affected by malignant ascites secondary to unresectable peritoneal carcinomatosis of gastric origin, in order to associate the benefits of a definitive palliation of ascites with a minimal invasiveness. All patients had ascites related symptoms requiring iterative paracenteses. Intraperitoneal perfusion of mitomycin-C and cisplatin was delivered for 60-90min with an inflow temperature of 45 degrees C.
RESULTS: Complete clinical regression of ascites and related symptoms was achieved in all the five patients treated. Intraoperative course was uneventful in all cases. Mean operative time was 181min. No postoperative deaths, related to the procedure, occurred. Only a case of delayed gastric empting was recorded as a minor postoperative complication.
CONCLUSIONS: Laparoscopic HIPEC appears to be a safe and effective procedure to treat debilitating malignant ascites from unresectable peritoneal carcinomatosis.

Entities:  

Mesh:

Year:  2007        PMID: 17640844     DOI: 10.1016/j.ejso.2007.05.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  35 in total

1.  Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ingmar Königsrainer
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

Authors:  Suma L Sangisetty; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2012-04-27

4.  Ascites do not affect the rate of complete cytoreductive surgery and prognosis in patients with primary ovarian cancer with ascites treated with hyperthermic intraperitoneal chemotherapy.

Authors:  Mingchen Ba; Hui Long; Xiangliang Zhang; Zhaofei Yan; Shuai Wang; Yinbing Wu; Yuanfeng Gong; Shuzhong Cui
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

Review 5.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

6.  Respiratory distress due to malignant ascites palliated by hyperthermic intraperitoneal chemotherapy.

Authors:  Marijn Marinus Leonardus van den Houten; Thijs Ralf van Oudheusden; Michael Derek Philip Luyer; Simon Willem Nienhuijs; Ignace Hubertus Johannes Theodorus de Hingh
Journal:  World J Gastrointest Surg       Date:  2015-03-27

7.  Intraperitoneal hyperthermic chemotherapy: which drugs?

Authors:  Jacopo Giuliani
Journal:  J Gastrointest Cancer       Date:  2014-03

8.  Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites.

Authors:  Mingchen Ba; Hui Long; Xiangliang Zhang; Yunqiang Tang; Yinbing Wu; Feihong Yu; Shuai Wang; Shuzhong Cui
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-22       Impact factor: 4.553

Review 9.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.